DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Sai Life Sciences Limited — Press Release

NSE 1 hr ago·6 Aug 2026, 5:53 pm

SAI Life Sciences

Sai Life Sciences Limited has informed stock exchanges about the release of its unaudited financial results for the quarter that ended on June 30, 2026. The company has issued a formal press release detailing its performance for this interim period, which investors can access on the exchange website.

This announcement is significant for shareholders as it provides an early look at the company's operational health and financial trajectory. While the unaudited figures are preliminary, they offer valuable insights into the company's current business momentum and help investors gauge its performance ahead of the final results.

Investors should monitor the release for updates on revenue growth, operational expenses, and any commentary from the management regarding future outlook. Keeping an eye on these details will be crucial for understanding the company's path forward in the competitive pharmaceutical sector.